Printer Friendly

Lithium is Clearly Underutilized in Child Psychiatry.

Byline: Ahmed. Naguy

To the Editor: Frederick Goodwin, an influential figure in bipolar mood disorder, famously said, if you can't, or you won't use lithium, get out from the business of treating bipolar disorders! Lithium remains the gold standard treatment of bipolar mood disorder. But, sorely, it is underutilized in Child/Adolescent Psychiatry, despite Food and Drug Administration's approval for age 12 and above. Recently, Findling et al. [sup][1]conducted the first randomized controlled trial for lithium in juvenile bipolar mood disorders ages 7–17 years where lithium was superior to placebo, well-tolerated, and, most importantly, devoid of the cardiometabolic syndrome inherent to most of the atypical antipsychotics that are currently the state-of-the-art treatment modality in most algorithms. Lithium was also shown to have a large effect size of 1.06 in an open treatment study by Kowatch et al .[sup][2] Geller et al .[sup][3] reported positive effects with reference to anti-manic efficacy in adolescents with bipolar and substance use disorders in a 6-week placebo-controlled double-blind study. In a meta-analysis by Liu et al .,[sup][4] a number of open-label trials demonstrated the average efficacy of 40%. In my opinion, lithium has fallen into disfavor as a viable treatment option for juvenile bipolar disorders for a couple of reasons. Lithium is notorious to have a narrow therapeutic index, and, hence toxicity is a definitive risk, notably in hot climates in countries like this, where kids can be readily dehydrated. I'd argue that with close monitoring of serum levels every 3 months as per British National Formulary, given higher metabolic rates and renal clearance resulting in a half-life of <18 h versus 24 h in adults, and, that lithium is excreted in sweat too, all this would translate clinically into surprisingly higher dosing than in adult counterparts to achieve therapeutic effects, and, ostensibly obviates undue concerns of toxicity in pediatric population. Another major concern is the dread of mental dullness effectuated by lithium in children where anti-cognitive effects would be counterproductive regarding academic demands. Heaps of data are pouring into neuroscience literature, all converging to demonstrate rather procognitive effects of lithium. These include, inter alia, increasing of gray matter volume, promoting of hippocampal neurogenesis, increasing of N-acetyl aspartate, a putative marker of neuronal viability, increasing brain-derived neutropic factor and anti-apoptotic Bcl-2, inhibition of pro-apoptotic protein P53 and [sz] catenin, and, inhibition of glycogen synthase kinase-3[sz]. For these properties, lithium has been tried in major neurodegenerative disorders like amyotrophic lateral sclerosis, although it was futile.

Uses of lithium in psychiatry are protean apart from bipolar mood disorders. Suffice to mention, anti-impulsivity, anti-suicidality, anti-aggressivity, dual diagnosis, schizo-affective, augmentation in unipolar depression, cyclothymia, cycloid psychosis, Klein–Levine syndrome, borderline personality, clozapine-induced neutropenia, augmentation in schizophrenia, psychogenic polydipsia, just to name few.

It behoves child and adolescent psychiatrists not to deprive this population from a “real “ mood-stabilizer that has withstood test of time for decades now, in the battle against the naturally more virulent juvenile bipolar disorders which take its toll relentlessly over lives of those afflicted kids and also their families, solely, for ill-founded fears in the eyes of prescribers.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Findling RL, Robb A, McNamara NK, Pavuluri MN, Kafantaris V, Scheffer R, et al. Lithium in the acute treatment of bipolar I disorder: A double-blind, placebo-controlled study. Pediatrics 2015;136:885-94. doi: 10.1542/peds.2015-0743.

2. Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000;39:713-20. doi: 10.1097/00004583-200006000-00009.

3. Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998;37:171-8. doi: 10.1097/00004583-199802000-00009.

4. Liu HY, Potter MP, Woodworth KY, Yorks DM, Petty CR, Wozniak JR, et al. Pharmacologic treatments for pediatric bipolar disorder: A review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2011;50:749-62.e39. doi: 10.1016/j.jaac.2011.05.011.
COPYRIGHT 2016 Medknow Publications and Media Pvt. Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Correspondence
Author:Naguy, Ahmed
Publication:Chinese Medical Journal
Article Type:Letter to the editor
Date:Mar 1, 2016
Words:704
Previous Article:Epidermoid Cyst Located in Facies Convexa Cerebri with Atypical Images.
Next Article:Clinical Misdiagnosis of Steatocystoma Simplex of Eyebrow in a Pediatric Patient.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |